Revumenib
Overview of the drug Revumenib
| Revumenib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Revumenib is an investigational drug that acts as an inhibitor of the menin-MLL interaction, which is implicated in certain types of acute leukemia. It is being studied for its potential use in treating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with specific genetic mutations.
Mechanism of Action[edit]
Revumenib functions by inhibiting the interaction between menin and mixed-lineage leukemia (MLL) proteins. This interaction is crucial for the proliferation of leukemia cells that harbor MLL rearrangements or NPM1 mutations. By disrupting this interaction, Revumenib aims to halt the growth of these cancerous cells and induce apoptosis.
Clinical Development[edit]
Revumenib is currently undergoing clinical trials to evaluate its safety and efficacy in patients with relapsed or refractory AML and ALL. These trials are particularly focused on patients with MLL rearrangements or NPM1 mutations, as these genetic alterations are known to drive the pathogenesis of these leukemias.
Pharmacokinetics[edit]
The pharmacokinetic profile of Revumenib is characterized by its absorption, distribution, metabolism, and excretion properties. It is designed to be administered orally, allowing for convenient dosing in a clinical setting. The drug's metabolism and elimination pathways are being studied to optimize its therapeutic window and minimize potential side effects.
Potential Side Effects[edit]
As with many investigational drugs, Revumenib may have side effects. Commonly observed adverse effects in clinical trials include cytopenias, gastrointestinal disturbances, and fatigue. Ongoing studies aim to further elucidate the safety profile of Revumenib and manage any adverse reactions effectively.
Future Directions[edit]
The development of Revumenib represents a promising advance in the targeted treatment of leukemias with specific genetic profiles. Future research will focus on combination therapies, resistance mechanisms, and expanding the indications for Revumenib to include other hematological malignancies.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
